| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.41M | 3.06M | 1.08M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.81M | 1.60M | 488.00K | -2.58M | -1.04M | -894.00K |
| EBITDA | -106.38M | -103.98M | -91.80M | -129.86M | -95.87M | -35.80M |
| Net Income | -106.46M | -101.01M | -95.96M | -141.04M | -88.95M | -36.61M |
Balance Sheet | ||||||
| Total Assets | 254.41M | 247.87M | 298.25M | 391.49M | 503.23M | 40.59M |
| Cash, Cash Equivalents and Short-Term Investments | 214.21M | 209.60M | 257.74M | 351.31M | 471.30M | 36.91M |
| Total Debt | 11.14M | 12.95M | 15.30M | 17.45M | 8.08M | 1.75M |
| Total Liabilities | 33.42M | 32.45M | 26.63M | 32.78M | 26.19M | 4.50M |
| Stockholders Equity | 220.98M | 215.42M | 271.62M | 358.71M | 477.03M | 36.09M |
Cash Flow | ||||||
| Free Cash Flow | -96.37M | -92.38M | -99.31M | -101.30M | -72.58M | -33.03M |
| Operating Cash Flow | -92.39M | -87.80M | -94.04M | -90.56M | -66.81M | -32.57M |
| Investing Cash Flow | -29.19M | -32.67M | 143.43M | 137.19M | -450.94M | -461.00K |
| Financing Cash Flow | 84.21M | 35.88M | 149.00K | 1.91M | 516.63M | 37.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $441.44M | ― | -46.87% | ― | 100.47% | -5.71% | |
| ― | $128.87M | -1.67 | -25.25% | ― | 12.13% | -8.23% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $326.31M | -5.12 | -26.77% | ― | ― | -24.60% | |
| ― | $230.08M | -3.28 | ― | ― | -31.30% | 36.26% | |
| ― | $270.54M | -1.73 | -85.21% | ― | ― | 38.94% | |
| ― | $675.13M | ― | -31.16% | ― | ― | 50.77% |
On September 26, 2025, Quantum-Si Incorporated entered into a Sales Agreement with Leerink Partners LLC to potentially offer and sell up to $100 million of its Class A common stock. The agreement allows for sales at the company’s discretion and is contingent upon the effectiveness of a shelf registration statement filed with the SEC. The arrangement provides flexibility in stock sales, with Leerink Partners acting as sales agent, and includes provisions for commissions and legal expense reimbursements. This strategic move could impact Quantum-Si’s market presence and financial strategy, although the company is not obligated to sell any shares.
The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.
Quantum-Si Incorporated and Winchester Office LLC have agreed to terminate their lease agreement for premises in New Haven, CT, originally set to expire in 2032. As part of the settlement, Quantum-Si will pay a termination fee of $11 million, adjusted for credits, and will have no further rent obligations after September 23, 2025.
The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.
On August 8, 2025, Quantum-Si Incorporated updated its corporate presentation, highlighting its strategic positioning and growth in the proteomics market. The company reported a 33% year-over-year growth in its user base for the first half of 2025 and announced the introduction of multiple instrument acquisition options. With a well-capitalized position and a cash runway into Q2 2028, Quantum-Si is poised to expand its market presence further. The company’s Proteus platform, expected to launch in the second half of 2026, is designed to address a broad range of proteomics analysis methods, potentially enhancing its competitive edge in the industry.
The most recent analyst rating on (QSI) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.
Quantum-Si Incorporated’s recent earnings call painted a picture of resilience and strategic adaptation amidst external challenges. The company emphasized its significant progress in technology development and strategic initiatives aimed at addressing market uncertainties. Despite revenue setbacks due to external factors, Quantum-Si is implementing new strategies to maintain its financial strength. The advancements in product offerings and a robust cash position contribute to a positive outlook for the company.
Quantum-Si Incorporated, a leader in proteomics technology, is revolutionizing protein analysis with its single-molecule detection platform. The company recently announced its second quarter 2025 financial results, highlighting significant developments in product offerings and financial performance.